Intech Investment Management LLC Has $3.56 Million Holdings in Neurocrine Biosciences, Inc. $NBIX

Intech Investment Management LLC reduced its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 20.9% in the 2nd quarter, Holdings Channel reports. The firm owned 28,348 shares of the company’s stock after selling 7,476 shares during the period. Intech Investment Management LLC’s holdings in Neurocrine Biosciences were worth $3,563,000 as of its most recent filing with the SEC.

A number of other large investors have also recently added to or reduced their stakes in NBIX. Geneos Wealth Management Inc. grew its position in Neurocrine Biosciences by 143.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after purchasing an additional 135 shares during the last quarter. WPG Advisers LLC acquired a new stake in shares of Neurocrine Biosciences during the 1st quarter worth approximately $32,000. SVB Wealth LLC bought a new stake in shares of Neurocrine Biosciences during the first quarter valued at approximately $35,000. True Wealth Design LLC raised its stake in shares of Neurocrine Biosciences by 1,215.4% in the second quarter. True Wealth Design LLC now owns 342 shares of the company’s stock valued at $43,000 after purchasing an additional 316 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its position in Neurocrine Biosciences by 6,285.7% in the first quarter. Caitong International Asset Management Co. Ltd now owns 447 shares of the company’s stock worth $49,000 after purchasing an additional 440 shares during the period. Institutional investors own 92.59% of the company’s stock.

Insider Buying and Selling

In other news, Director William H. Rastetter sold 18,000 shares of Neurocrine Biosciences stock in a transaction that occurred on Wednesday, November 5th. The shares were sold at an average price of $151.82, for a total value of $2,732,760.00. Following the completion of the sale, the director directly owned 40,360 shares in the company, valued at approximately $6,127,455.20. The trade was a 30.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Kyle Gano sold 300 shares of the business’s stock in a transaction that occurred on Tuesday, November 4th. The shares were sold at an average price of $141.97, for a total transaction of $42,591.00. Following the completion of the transaction, the chief executive officer owned 140,407 shares of the company’s stock, valued at $19,933,581.79. The trade was a 0.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 4.80% of the company’s stock.

Neurocrine Biosciences Stock Down 3.4%

Neurocrine Biosciences stock opened at $138.63 on Wednesday. The company has a 50 day moving average of $142.53 and a 200-day moving average of $133.50. The stock has a market capitalization of $13.82 billion, a PE ratio of 33.17, a price-to-earnings-growth ratio of 0.94 and a beta of 0.22. Neurocrine Biosciences, Inc. has a twelve month low of $84.23 and a twelve month high of $157.67.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Tuesday, October 28th. The company reported $2.17 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.59. Neurocrine Biosciences had a return on equity of 15.82% and a net margin of 15.95%.The firm had revenue of $794.90 million during the quarter, compared to the consensus estimate of $746.61 million. During the same period last year, the company earned $1.81 earnings per share. The business’s revenue was up 27.8% compared to the same quarter last year. Equities analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Stifel Nicolaus upped their target price on shares of Neurocrine Biosciences from $174.00 to $183.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Wedbush reaffirmed an “outperform” rating on shares of Neurocrine Biosciences in a report on Monday, September 22nd. Canaccord Genuity Group increased their target price on Neurocrine Biosciences from $160.00 to $164.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Guggenheim boosted their price target on Neurocrine Biosciences from $165.00 to $175.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Finally, Truist Financial reissued a “buy” rating and set a $172.00 price objective (up from $165.00) on shares of Neurocrine Biosciences in a report on Thursday, October 30th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $170.53.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.